Appeal 2007-1070
Application 09/467,901
to contact with the IgE receptor to simulate in vivo interactions
between the IgE antibody, the ligand, and the IgE receptor,
(c) separating the carrier-bound IgE-containing
complexes from the mixture II, and
(d) detecting and/or quantifying physiologically active
forms of ligand-specific IgE bound to said receptor by
determining the amount of the carrier-bound IgE-containing
complexes formed by detecting a label present in the carrier-
bound IgE-containing complexes,
wherein the label to be detected is associated with the ligand or
the IgE antibody and wherein the label to be detected is added
to the complexes present in steps (a), (b), or (c) and does not
form part of the carrier and wherein in vivo interactions
between the IgE antibody, the IgE antibody’s ligand and the
IgE antibody’s receptor are simulated to measure
physiologically active forms of IgE.
FINDINGS OF ACT
Johansen
1. Johansen describes an IgE assay which is specific for an IgE antibody;
the IgE antibody recognizes a specific antigen or hapten of interest
(Johansen, col. 4, ll. 50-62 and col. 5, ll. 50-60; Answer 4).
2. The assay contains: 1) specific IgE-antibody; 2) a specific allergen
(antigen or hapten) bound to biotin; 3) a monoclonal mouse anti-IgE bound
to magnetic particles; and 4) a chemiluminescent avidin-acridinium ester
label (Johansen, col. 5, ll. 50-60; Answer 4).
3. The specific IgE-antibody (present in a “sample”) is mixed with the
specific allergen bound to biotin (“ligand antigen”) and the anti-IgE bound
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: September 9, 2013